Vincaleukoblastine, 22-oxo-
Vincaleukoblastine, 22-oxo- Brand names, Vincaleukoblastine, 22-oxo- Analogs
- 22-Oxovincaleukoblastine
- Indole alkaloid
- LCR
- Leurocristine
- Onco TCS
- Oncovin
- Oncovin (1:1 sulfate salt)
- VCR
- VIN
- Vincaleukoblastine, 22-oxo-
- Vincasar (1:1 sulfate salt)
- Vincasar PFS
- Vincrex
- Vincrex (1:1 sulfate salt)
- Vincristina [DCIT]
- Vincristine Sulfate
- Vincristine Sulfate PFS
- Vincristinum [INN-Latin]
- Vincrstine
- Vincrystine
- Vinkristin
- Z-D-Val-Lys(Z)-OH
Vincaleukoblastine, 22-oxo- Brand Names Mixture
- No information avaliable
Vincaleukoblastine, 22-oxo- Chemical_Formula
C46H56N4O10
Vincaleukoblastine, 22-oxo- RX_link
http://www.rxlist.com/cgi/generic3/vincristine.htm
Vincaleukoblastine, 22-oxo- fda sheet
Vincaleukoblastine, 22-oxo- msds (material safety sheet)
Vincaleukoblastine, 22-oxo- Synthesis Reference
No information avaliable
Vincaleukoblastine, 22-oxo- Molecular Weight
824.958 g/mol
Vincaleukoblastine, 22-oxo- Melting Point
220 oC
Vincaleukoblastine, 22-oxo- H2O Solubility
No information avaliable
Vincaleukoblastine, 22-oxo- State
Solid
Vincaleukoblastine, 22-oxo- LogP
4.918
Vincaleukoblastine, 22-oxo- Dosage Forms
Liquid; Solution
Vincaleukoblastine, 22-oxo- Indication
For treatment of acute leukaemia, malignant lymphoma, Hodgkin's disease, acute erythraemia, acute panmyelosis
Vincaleukoblastine, 22-oxo- Pharmacology
Vincristine is a vinca alkaloid antineoplastic agent used as a treatment for various cancers including breast cancer, Hodgkin's disease, Kaposi's sarcoma, and testicular cancer. The vinca alkaloids are structurally similar compounds comprised of 2 multiringed units, vindoline and catharanthine. The vinca alkaloids have become clinically useful since the discovery of their antitumour properties in 1959. Initially, extracts of the periwinkle plant (Catharanthus roseus) were investigated because of putative hypoglycemic properties, but were noted to cause marrow suppression in rats and antileukemic effects in vitro. Vincristine binds to the microtubular proteins of the mitotic spindle, leading to crystallization of the microtubule and mitotic arrest or cell death. Vincristine has some immunosuppressant effect. The vinca alkaloids are considered to be cell cycle phase-specific.
Vincaleukoblastine, 22-oxo- Absorption
No information avaliable
Vincaleukoblastine, 22-oxo- side effects and Toxicity
IVN-RAT LD50 1300 mg/kg; IPR-MUS LD50 5.2 mg/kg
Vincaleukoblastine, 22-oxo- Patient Information
PATIENT INFORMATION
Follow the links
http://www.rxlist.com/cgi/generic3/vincristine_wcp.htm
http://www.drugs.com/cons/Vincristine.html
Follow the links
http://www.rxlist.com/cgi/generic3/vincristine_wcp.htm
http://www.drugs.com/cons/Vincristine.html
Vincaleukoblastine, 22-oxo- Organisms Affected
Humans and other mammals
